OSAA Innovation develops innovative medical devices and smart connected solutions to revolutionize intravenous (IV) therapy, focusing on improving patient mobility, convenience, safety, and overall quality of life. Pulse 2.0 interviewed OSAA Innovation founder and CEO Ahmed Hessam to gain a deeper understanding of the company.
Ahmed Hessam’s Background
What is Ahmed Hessam’s background? Hessam said:
“My name is Ahmed Hessam. I am CEO and Founder of OSAA Innovation – Danish medtech company revolutionising IV treatment solutions in healthcare. I was born in Iraq but at the age of 9 I moved to Denmark which became my second home.”
“Since my teenage years, I have always been curious about devising smart solutions for often overlooked areas. This inspired me to obtain an Industrial designer degree from the Zealand Academy of Technologies and Business (Denmark) which in a way became the starting point of my entrepreneurship journey.”
Formation Of The Company
How did the idea for the company come together? Hessam shared:
“Throughout my youth, I experienced the Danish healthcare system firsthand, since I was a long-term patient. It shaped my understanding of patient needs. So to say, the inspiration for the company’s novelty product iV-GO infusion pump essentially came during one of my hospitalizations where I saw a young girl playing outside while her mother struggled to carry her IV bag. Frustrated by the limitations imposed on patients by traditional IV bags and poles, I sought to create a solution.”
“In 2009, merging my passions for design, engineering, technology, and business, I got a visionary idea that would change the landscape of IV treatments. I created the first prototype of iV-GO – a lightweight and portable 100% mechanical device that stands out for its unique feature – it allows patients to be mobile during treatments. Since then recognizing the challenges faced by patients, nurses and doctors, I kept working on this concept which laid the groundwork for the establishment of OSAA Innovation in 2016.”
“Stepping further, the OSAA Innovation team has been dedicated to creating solutions that empower and destigmatize patients undergoing IV treatments. With the help of smart IV solutions within the OSAA Innovation’s ecosystem, we are committed to building a future in healthcare where patients can maintain their dignity and experience the unparalleled patient-centered care, while the industry can focus on enhancing the patients’ results and avoid the unnecessary financial burdens associated with traditional IV delivery systems.”
Favorite Memory
What has been your favorite memory working for the company so far? Hessam reflected:
“One of the proudest and happiest moments for me and for the whole OSAA Innovation’s team was during the last Medica trade fair, where we unveiled our portfolio of devices to the expert community and customers visiting our stand. It was fantastic to see all the ideas realized.”
“I have always strove to help people needing IV, but with the extended portfolio I truly believe we can make a big difference.”
Core Products
What are the company’s core products and features? Hessam explained:
“OSAA Innovation product ecosystem is a comprehensive and interconnected network of cutting-edge medical devices designed to enhance clinical workflows and improve healthcare outcomes for patients.”
The ecosystem features two distinct product series:
- The GO-series – This series includes mechanical pressure pumps that empower patients with increased mobility during IV treatment. Designed for flexibility, the GO-series eliminates the need for gravity or IV poles, allowing patients to move freely while receiving care.
- The VITA-series – the VITA-series includes lightweight infusion monitors and infusion pumps that provide unprecedented real-time monitoring capabilities, both on the device and remotely. With each generation, the VITA-series enhances user experience and clinical effectiveness, ensuring that healthcare providers can deliver precise and timely treatment.
At the core of the OSAA Innovation’s IV ecosystem is iV-View solution, a web-based dashboard that enables hospital staff to track all connected OSAA IV devices allocated across the different wards and monitor several patients’ infusion statuses from a single station.
The newest add-on to OSAA Innovation’s product ecosystem is iV-Warmer for transfusions that can help prevent hypothermia and improve patient comfort during IV therapy.”
Challenges Faced
What challenges have Hessam and the team faced in building the company? Hessam acknowledged:
“A big challenge many SMEs face is adapting to the rapidly changing market dynamics. For instance when I started the company in 2016 the at-home infusion therapy care was still an area which was growing slowly. But several years later the industry faced some significant developments while adhering to patients’ needs and moving the delivery of infusions from the traditional hospital settings to the infusion clinics and at-home infusion care.”
“So to say, only across the U.S. in 2020, according to NHIA estimations there were 974 providers of home and specialty infusion serving more than 3.2 million patients each year. This shift was further prompted by the Covid-19 pandemic, which underscored the necessity of moving patients out from hospitals to alternative care settings and specifically patients’ homes, thereby reducing the risk of cross-contamination.”
“Appearance of at-home infusion care meant that healthcare professionals had to be equipped with the right tools to have remote access to the treatment status and act immediately in case of any disruptions. For us it meant that our product ecosystem should offer connected solutions for remote treatment monitoring and remote treatment regulation.”
“It required a slight shift in our focus and additional resources to facilitate the market needs, but at the same time it created the ground for a new cycle of innovation in our company.”
“Today the majority of our devices are connected, portable and equip the healthcare professional with the capability to remotely monitor infusion treatments effectively, stay on top of the treatment status and ensure the patient’s safety.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Hessam noted:
“OSAA Innovation’s first product iV-GO World’s First Portable 100% Mechanical IV Pump was released in 2022. iV-GO is a lightweight and portable 100% mechanical device that allows patients to be mobile during IV treatments. It has garnered international attention as the company has won a variety of awards, including the Red Dot Design (2022), Good Design (2023), Australian Good Design (2024) and German Design Awards (2025).”
“Since the introduction of the award-winning iV-GO, OSAA Innovation’s team has made a significant effort on focusing on the product expansion and as well adhering to industry trends and patients’ needs while specifically focusing on connectivity and remote-patient monitoring when it comes to the product development and innovation.”
“Currently, the company ecosystem expanded to a suite of products, including connected iV2GO and iV2Vita with IoT monitoring, smart sensors and dashboard software, and the iV4GO Pro and iV4Vita Pro — an advanced infusion rate monitor and regulator designed to enhance the safety and efficiency of intravenous therapy.”
“The newest add-on to OSAA Innovation’s product ecosystem is iV-Warmer for transfusions that can help prevent hypothermia and improve patient comfort during IV therapy.”
Significant Milestones
What have been some of the company’s most significant milestones? Hessam cited:
“Product development & Regulatory compliance:
Product development milestone goes hand in hand with the other important milestone for OSAA Innovation, which is regulatory compliance.
Currently, OSAA Innovation’s equipment complies with ISO 1345 medical device standards, and the iV-GO is certified in Europe, Australia, and Saudi Arabia, with additional devices currently undergoing regulatory approval processes.
Market expansion:
Market expansion is one of key milestones for OSAA Innovation. Today the company is actively present in Scandinavian markets, Australia, Saudi Arabia and Poland, creating a strong distribution network and meeting the needs of the patients and healthcare institutions in different regions.
Having more markets in mind, in 2025 we are working in a close collaboration with our Business consultants to evaluate the other market’s needs and challenges, understand the healthcare settings and to enlarge our distribution network even further.
Awards
OSAA Innovation has been continuously recognised by the series of design and entrepreneurship awards in Denmark and globally, which reflects their dedication to enhancing the patient experience through thoughtful and functional design.
Among the most prominent awards: Danish Design awards winner (2021), Red Dot Design Winner (2023), Good Design Award (2023), Australian Good Design (2024) and German Design Awards (2025).
These awards collectively showcase our commitment to pushing the boundaries of design and technology, ultimately benefiting patients and healthcare providers alike.”
Customer Success Stories
When asking Hessam about customer success stories, he highlighted:
“Speaking of the memorable customer stories, I would like to mention the one from one of our earlier users, named Hans, who was going through a 9 months-period of regular (2-3 times a week) IV administration of high-dose Vitamin C. Each session involved approximately 1000ml of Vitamin C and lasted around 90 minutes. During this time, Hans found himself “tied” to an IV pole, with limited ability to engage in daily activities around the house and garden.”
“The introduction of iV-GO portable 100% mechanical IV-pump as a part of Hans’s healthcare journey, significantly transformed his treatment experience by restoring his mobility indoors, while iV-BACK extended that freedom outdoors. This innovative equipment significantly simplified the management of his illness, making daily life much more satisfactory.”
Funding
When asking Hessam about the company’s funding details, he revealed:
“At OSAA Innovation, we greatly appreciate our investors for their valuable know-how and expertise. It’s crucial for us to actively involve them in various processes, as they are an integral part of our team.”
“Over the years, we have successfully raised €5.5 million over the years. This funding not only provides the necessary capital for growth but also brings invaluable mentorship and guidance from our investors, helping to shape our strategies and operations.”
Total Addressable Market
What total addressable market (TAM) size is the company pursuing? Hessam assessed:
“When it comes to the total addressable market for OSAA Innovation, there are different factors which can be taken into account.”
“First and foremost it is important to highlight that approximately 90% of hospitalizations globally require some form of IV therapy inclusive of intravenous (IV) medication, fluids and blood products delivered to patients via infusion pumps, making infusion therapy a cornerstone of modern healthcare. Therefore it is essential to provide nurses and clinicians with the right tools and equipment to support efficient workflows and patient safety. Nevertheless infusion therapy is still perceived as one of the most traditionalized healthcare industries. So to say one of the key medical equipment solutions for IV, IV pole, has remained largely the same since the early 1900s, except for the addition of wheels. Not surprising for 75% of nurses, mobilization is the biggest challenge while using the IV pole.”
“Both these factors highlight the significant emerging need for innovation for medical equipment producers in the industry and therefore significantly expand market opportunity for OSAA Innovation.”
“Additionally, according to new market research conducted by iData Research, the U.S. infusion therapy market size was valued at over $3.2 billion in 2022 and its CAGR is expected to be 2.5% over the forecasting period (2023–2029). This growth can be attributed to a number of factors, including the increasing prevalence of chronic diseases such as cancer and diabetes, the increase in the elderly population, and advancements in technology that have made infusion therapy more efficient and accessible. Source.”
“In summary, the combination of an expanding market, ongoing challenges in IV therapy, and a pressing need for innovation presents a significant opportunity for OSAA Innovation to transform medical equipment and enhance patient care in the infusion therapy sector.”
Differentiation From The Competition
What differentiates the company from its competition? Hessam affirmed:
“OSAA Innovation operates in the industry of infusion therapy along with such established players as BD, Baxter, Fresenius, B. Braun, Medtronic, ICU Medical who are serving the majority of the infusion therapy market. Yet recent market challenges, notably, Baxter IV fluids crisis have obviously shown that the infusion market needs more flexible players to leverage innovative technologies and delivery systems under a pressured timeline. Small to medium-sized companies such as OSAA Innovation can drive the innovation needed to address these pressures since they can be more responsive to immediate market changes.”
“When it comes to the product development unlike of many other players on the market, we at OSAA Innovation pursue 3 areas, when it comes to the product development: mobility of patients, device connectivity, and prevention of usability errors.”
“For example to address the usability errors, we regularly return to hospitals to gather feedback on new features, ensuring our designs are intuitive and practical. When nurses feel involved in the process, they’re more likely to adopt and continue using the device once it’s launched.”
“When it comes to mobility, with the ongoing evolution of healthcare recovery protocols, patients undergoing major surgeries are now encouraged to regain mobility much earlier than in previous decades. For instance, early mobilization following orthopaedic surgery has become increasingly important while parenteral antimicrobial therapy is now often provided in outpatient settings.”
“These changes in treatment setting and delivery have highlighted the need for a greater number of mobile versatile IV options.”
“And this is where OSAA Innovation and our products can absolutely make a difference. Our Mobility focused infusion pumps liberate individuals from the constraints of hospital beds and IV poles, allowing for treatment “on the go”—whether in hospitals, at home, or in the other alternative care setting.”
“When it comes to connectivity, as healthcare systems become more digitally enabled, infusion therapy being one of the fundamental elements of modern healthcare, continues to evolve. Not surprising that medical devices such as infusion pumps, infusion monitors or drip counters today are not only perceived as a tool for a routine service delivery. With the appearance of connectivity the value of medical devices has been redefined, now incorporating the critical ability to provide clinicians with patient-level data and real-time information on treatment status.”
“At OSAA Innovation we consider connectivity as one of the biggest drivers when it comes to the development of the infusion therapy industry itself and as well the catalyzer the product innovation when it comes to our own ecosystem.”
Future Company Goals
What are some of the company’s future goals? Hessam emphasized:
“When it comes to the future company goals, there are several directions which company would like to pursue in the near future:
✔️Promotion of Enhanced Patient-Centric Care: At OSAA Innovation, we design our IV solutions with patients in mind. In 2025 we aim to work towards personalization of infusion therapy by leveraging treatment data analytics and patient feedback to make sure our solutions are versatile and are tailored for individual needs.
✔ ️Leveraging Patient feedback as a catalyst for a change: At OSAA Innovation, we recognize that listening to patients is crucial. In 2025, we believe that our users will play a vital role in driving transformation in infusion therapy and therefore impacting our product innovations by voicing their needs, goals, and expectations.
✔️ Expansion of cross-collaboration in the industry: At OSAA Innovation we believe that collaboration is key to driving meaningful change. In 2025 we aim to work closely with healthcare professionals, researchers, and technology partners to share knowledge and develop IV solutions that benefit all stakeholders.”
